Global Pharmaceutical Intermediates Market to Reach $38.9 Billion in 2026, Green Synthesis Becomes Mainstream

来源: Precedence Research
链接: https://www.precedenceresearch.com/pharmaceutical-intermediates-market

# Market Size and Growth

According to the latest report from Precedence Research, the global pharmaceutical intermediates market was valued at $37.04 billion in 2025, is projected to grow from $38.90 billion in 2026, and reach $59.70 billion by 2035, with a compound annual growth rate (CAGR) of 4.89% during the 2026-2035 period.

# Market Drivers

## Increasing Chronic Disease Burden
The growing global burden of chronic diseases is driving demand for drugs. According to World Health Organization data, diabetes is a major cause of stroke, heart attacks, and kidney failure. The geriatric population is expected to reach nearly 2 billion by 2050, factors driving global demand for pharmaceutical intermediates.

## Rapid Biopharmaceutical Industry Growth
The biopharmaceutical industry accounts for approximately 20% of the global pharmaceutical industry and is expected to be one of the major growth drivers in the coming years. The rapid growth of the biopharmaceutical industry is driven by the development of various life-saving drugs that can treat cancers, tumors, and various chronic diseases with minimal side effects.

## AI Application
Artificial intelligence is being profoundly applied in the pharmaceutical industry, particularly in the pharmaceutical intermediates market, by improving efficiency, reducing costs, and accelerating innovation across the entire value chain from R&D to manufacturing and supply chain management. Machine learning models improve supply chains by managing inventory levels, forecasting demand patterns, and more effectively streamlining logistics.

# Segment Analysis

## By Product
The bulk drug intermediates segment accounted for the largest revenue share in 2024. Bulk drug intermediates are widely used to manufacture active pharmaceutical ingredients (APIs). Government initiatives to promote and develop bulk drug parks are expected to drive growth in this segment.

## By Application
The analgesics segment accounts for approximately 30% of the global pharmaceutical intermediates market and is expected to maintain its dominance in the near future. Anti-cancer drugs are expected to grow rapidly during the forecast period.

## By End User
The CROs/CMOs segment led the global pharmaceutical intermediates market in revenue in 2023 and is expected to maintain its dominance during the forecast period. The rapid penetration and growth of contract manufacturing organizations and contract research organizations have significantly driven demand for pharmaceutical intermediates for production and research purposes.

# Technology Trends

## Green Synthesis Technology
The report specifically mentions that the adoption of green synthesis technology, continuous flow chemistry, and AI are major trends. This has significant implications for organic synthesis service providers like Wuhan Henrysintai, and we have already invested heavily in these advanced technologies.

## High-Potency and Chiral Intermediates
Market demand for high-potency drug intermediates (such as ADC drug intermediates) and chiral intermediates is growing. These high-difficulty synthesis areas are exactly where Wuhan Henrysintai’s core strengths lie.

## Supply Chain Optimization
The application of AI technology in supply chain management helps improve efficiency, avoid stock shortages or overstocks, particularly important for sensitive materials such as drug intermediates.

# Regional Markets

## North American Market
North America dominated the global pharmaceutical intermediates market in 2024 and is expected to maintain its dominance during the forecast period. North America’s dominance is attributed to the presence of numerous pharmaceutical companies, research centers, and laboratories, as well as rapidly growing CMOs and CDMOs.

## Asia-Pacific Market
The Asia-Pacific region is expected to be the fastest-growing market, with developing countries such as China, India, South Korea, and Australia being the main contributors to growth in the region.

# Company Commentary

As a professional organic synthesis service provider, Wuhan Henrysintai is fully capitalizing on the growth opportunities in the global pharmaceutical intermediates market. Our core strengths perfectly align with market trends:

## Green Synthesis Technology Leadership
We have made green synthesis technology a core strategy, reducing production costs and improving product quality through environmentally friendly processes to meet global sustainability requirements.

## ADC Intermediates Expertise
With the rapid growth of the ADC drug market, our synthesis capabilities for high-purity ADC intermediates (including linkers and payloads) have become a competitive advantage. Our high-purity synthesis technology can meet the strict quality requirements of ADC drugs for intermediates.

## Chiral Intermediate Advantages
Our technical accumulation in chiral intermediate synthesis enables us to meet the high-purity requirements of anti-cancer drugs and other complex drugs for chiral raw materials.

## AI-Driven Supply Chain Management
We are introducing AI technology to optimize supply chain management, improve efficiency, reduce costs, and provide more reliable services to customers.

As an important promoter of domestic substitution, we are committed to providing high-quality pharmaceutical intermediates for global pharmaceutical companies through self-developed technology and innovation, helping partners accelerate new drug development and clinical progress.